Phoenix Bio

研究開発

研究開発

In vivo stable transduction of humanized liver tissue in chimeric mice via high-capacity adenovirus-lentivirus hybrid vector.

    Kubo S, Kataoka M, Tateno C, Yoshizato K, Kawasaki Y, Kimura T, Faure-Kumar E, Palmer DJ, Ng P, Okamura H, Kasahara N.

    Hum Gene Ther. 2010 Jan;21(1):40-50.

    Activation of Morphine Glucuronidation by Fatty Acyl-CoAs and Its Plasticity: A Comparative Study in Humans and Rodents Including Chimeric Mice Carrying Human Liver.

    Nurrochmad A, Ishii Y, Nakanoh H, Inoue T, Horie T, Sugihara K, Ohta S, Taketomi A, Maehara Y, Yamada H.
    Drug Metab Pharmacokinet. in press.

    ヒト型肝臓を持つキメラマウスから分離したヒト肝細胞のCYPおよびUGT活性の評価

    Yamasaki, C., et al

    DMPK. 2010; 6:45

    ヒト肝細胞キメラマウスを用いた治療抵抗性の肝炎に関する研究

    茶山一彰

    研究班会議

    ヒト肝細胞キメラマウス

    立野知世

    総合臨床 2010; 59(2): 297-298

    Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry.

      Yamazaki H, Kuribayashi S, Inoue T, Tateno C, Nishikura Y, Oofusa K, Harada D, Naito S, Horie T, Ohta S.
      Chem Res Toxicol. 2010 Jan;23(1):152-8.

      In vivo modeling of human liver for pharmacological study using humanized mouse.

        Yoshizato K, Tateno C.

        Expert Opin Drug Metab Toxicol. 2009 Nov;5(11):1435-46.

        Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice.

          Hiraga N, Imamura M, Hatakeyama T, Kitamura S, Mitsui F, Tanaka S, Tsuge M, Takahashi S, Abe H, Maekawa T, Ochi H, Tateno C, Yoshizato K, Wakita T, Chayama K.
          J Hepatol. 2009 Dec;51(6):1046-54. Epub 2009 Sep 23.

          A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans.

            Yoshizato K, Tateno C.

            PPAR Res.2009:476217. Epub 2009 Oct 26.

            Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry.

              Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau JM, Cosset FL, Chayama K, Vaillant A, Liang TJ.
              Gastroenterology. 2009 Aug;137(2):673-81

              Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice.

                Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T, Chayama K, Ohdan H.

                J Clin Invest. 2009 Nov;119(11):3226-35.

                A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J.

                  Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, Nakayoshi T, Wakuta M, Miyakawa Y, Mizokami M.

                  J Virol. 2009 Oct;83(20):10538-47.

                  CYP1A1 and CYP1A2 expression: comparing ‘humanized’ mouse lines and wild-type mice; comparing human and mouse hepatoma-derived cell lines.

                    Uno S, Endo K, Ishida Y, Tateno C, Makishima M, Yoshizato K, Nebert DW.
                    Toxicol Appl Pharmacol. 2009 May 15;237(1):119-26.

                    Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes.

                      Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S, Shirai T, Hino K, Sakaida I, Mizokami M.
                      Gastroenterology. 2009 Feb;136(2):652-62

                      ヒト肝キメラマウスの特性

                      特免編集部

                      シリーズIII: 継続・肝炎ウイルス十話_第一話

                      Prediction of Human Disposition toward S-3H-Warfarin using Chimeric Mice with Humanized Liver

                        Tae INOUE, Kazumi SUGIHARA, Hiroki OHSHITA, Toru HORIE, Shigeyuki KITAMURA and Shigeru OHTA
                        Drug Metabolism and Pharmacokinetics Vol. 24 (2009) , No. 2 pp.153-160

                        Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes.

                          Tabuchi A, Tanaka J, Katayama K, Mizui M, Matsukura H, Yugi H, Shimada T, Miyakawa Y, Yoshizawa H.
                          J Med Virol. 2008 Dec;80(12):2064-8.

                          CYP2C9-Catalyzed Metabolism of S-Warfarin to 7-Hydroxywarfarin in Vivo and in Vitro in Chimeric Mice with Humanized Liver.

                            Inoue T, Nitta K, Sugihara K, Horie T, Kitamura S, Ohta S.
                            Drug Metab Dispos. 2008 Dec;36(12):2429-2433

                            Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b.

                              Kurbanov F, Tanaka Y, Chub E, Maruyama I, Azlarova A, Kamitsukasa H, Ohno T, Bonetto S, Moreau I, Fanning LJ, Legrand-Abravanel F, Izopet J, Naoumov N, Shimada T, Netesov S, Mizokami M.
                              J Infect Dis. 2008 Nov 15;198(10):1448-56.

                              Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice.

                                Okada K, Shoda J, Taguchi K, Maher JM, Ishizaki K, Inoue Y, Ohtsuki M, Goto N, Takeda K, Utsunomiya H, Oda K, Warabi E, Ishii T, Osaka K, Hyodo I, Yamamoto M.
                                Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G735-47. Epub 2008 Aug 7.